Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Belsomra Most Heavily Pitched Drug in November: Anterio
January 7, 2016
- Novartis, Chugai to Close Out Comarketing Scheme for Femara
January 7, 2016
- Takeda, French Startup Tie Up on Gut Bacteria-Derived Drugs for GI Disorders
January 7, 2016
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
- Generic Use Rate at 54.7% in July-September 2015: JGA
January 6, 2016
- Fuji Pharma Licenses Nesp Biosimilar from S. Korean Firm
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Torii Files NDA for Allergen Immunotherapy Tablet for Cedar Pollinosis
January 5, 2016
- ASKA Files Rifaximin for Hepatic Encephalopathy
December 25, 2015
- Bristol-Myers Files Elotuzumab for Relapsed, Refractory Multiple Myeloma in Japan
December 25, 2015
- FDA OKs Selexipag Originated by Nippon Shinyaku
December 24, 2015
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- Israel’s Pluristem Therapeutics to Enter into Japanese Regenerative Medicine Market
December 24, 2015
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…